Cytarabine (Synonyms: 阿糖胞苷; Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

目录号: HY-13605 纯度: 99.98%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Cytarabine 是一种核苷类似物，可引起 S 期细胞周期停滞并抑制 DNA聚合酶。Cytarabine 抑制DNA 合成的IC₅₀为16 nM。Cytarabine 对 HSV 具有抗病毒作用。Cytarabine 具有抗正痘活性。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 147-94-4

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥500	In-stock
500 mg	￥920	In-stock
1 g	￥1100	In-stock
5 g		询价
10 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Cytarabine:

MCE 顾客使用本产品发表的 80 篇科研文献

Cell Viability Assay

: Cytarabine purchased from MCE. Usage Cited in: Cell Rep Med. 2024 Sep 27:101770. [Abstract]; Cell viability of WiT49-parental and WiT49-PRC-1 cells treated with cytarabine. IC50 is shown in the figure. The WiT49-PRC-1 cells are 100-fold more sensitive to cytarabine and 20-fold more sensitive to alisertib than the parental WiT49 cells.

: Cytarabine purchased from MCE. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]; TF-1 clones are incubated with 2 µM Cytarabine (araC) for up to 10 or 12 h, and cleaved caspase-3 is detected by immunoblot analysis.

: Cytarabine purchased from MCE. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]; TF-1 clones were incubated with 2 µM araC or 1 µM DNR for up to 10 or 12 h, respectively, and cleaved caspase-3 was detected by immunoblot analysis. GAPDH was used as loading control.

Cytarabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSV 亚型特异性产品:

查看所有亚型

HSV-1 HSV-2 HSV

生物活性
实验参考方法
纯度 & 产品资料
参考文献

生物活性

Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC₅₀ of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

IC₅₀ & Target^[1]

Microbial Metabolite

HSV-1

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
143B	IC₅₀	16.88 μM Compound: Cytarabine	Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
143B	IC₅₀	2.06 μM Compound: Cytarabine	Cytotoxicity against human 143B cells after 72 hrs by SRB assay Cytotoxicity against human 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
A-375	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against A-375 cell line human melanoma Tested in vitro against A-375 cell line human melanoma	[PMID: 8277499]
A549	GI₅₀	0.2 μM Compound: Ara-C	Growth inhibition of human A549 cells after 24 hrs by WST-1 assay Growth inhibition of human A549 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
A549	IC₅₀	0.83 μM Compound: ara-C	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
A549	IC₅₀	1.2 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
A549	IC₅₀	1.75 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
A549	IC₅₀	1.9 μM Compound: 1, ara-C	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 19691349]
A549	IC₅₀	1.9 μM Compound: 2, Ara-C	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24956556]
A549	IC₅₀	1.9 μM Compound: AraC	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 38716896]
A549	IC₅₀	202.57 μM Compound: CAR	Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]
A549	IC₅₀	3.47 μM Compound: ara-C	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	49.27 μg/mL Compound: CAR	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
A549	IC₅₀	620 μM Compound: cytarabine	Cytotoxicity against A549 cells after 72 hrs by SRB assay Cytotoxicity against A549 cells after 72 hrs by SRB assay	[PMID: 17419604]
AMML	IC₅₀	2.3 μM Compound: ara-C	Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia) Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)	[PMID: 3761322]
B16	IC₅₀	0.24 μg/mL Compound: Ara-C	In vitro inhibitory activity against Mouse melanoma (B16) cell line. In vitro inhibitory activity against Mouse melanoma (B16) cell line.	[PMID: 1995905]
B16	IC₅₀	30.62 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 21620529]
B16	IC₅₀	49.22 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
BALL-1	GI₅₀	0.08 μM Compound: Ara-C	Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
Bel-7402	IC₅₀	34.2 μM Compound: Ara-C	Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20692841]
Bone marrow cell	GI₅₀	64.1 μM Compound: Cytarabine	Growth inhibition of human bone marrow cells Growth inhibition of human bone marrow cells	[PMID: 29995404]
CAKI-1	IC₅₀	> 5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against renal CAKI-1 cells In vitro cytotoxicity was evaluated against renal CAKI-1 cells	[PMID: 10780904]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Effective dose to inhibit the replication of S180 cell line in vitro. Effective dose to inhibit the replication of S180 cell line in vitro.	[PMID: 1995894]
CCRF S-180	IC₅₀	25.43 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	[PMID: 21620529]
CCRF S-180	IC₅₀	40.33 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
CCRF-CEM	EC₅₀	0.00561 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	EC₅₀	0.0228 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	ED₅₀	0.005 μM Compound: ara-C	Inhibit the replication of CCRF-CEM cell line in vitro. Inhibit the replication of CCRF-CEM cell line in vitro.	[PMID: 1995894]
CCRF-CEM	ED₅₀	0.006 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF-CEM	ED₅₀	120 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-) Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)	[PMID: 1652024]
CCRF-CEM	GI₅₀	0.09 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	GI₅₀	0.0998 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	IC₅₀	0.001 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay	[PMID: 19674903]
CCRF-CEM	IC₅₀	0.0037 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
CCRF-CEM	IC₅₀	0.006 μM Compound: Ara-C	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
CCRF-CEM	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against human CEM cells after 2 days Cytotoxicity against human CEM cells after 2 days	[PMID: 19910080]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.	[PMID: 1992123]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.	[PMID: 3373480]
CCRF-CEM	IC₅₀	0.09 μM Compound: 6	In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM). In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).	[PMID: 8917645]
CCRF-CEM	IC₅₀	0.32 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.	[PMID: 1995905]
CCRF-CEM	IC₅₀	6.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-CEM/ara-C	IC₅₀	0.0001 M Compound: Ara-C	Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-HSB-2	IC₅₀	0.0086 μg/mL Compound: araC	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 18723355]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: AraC	Growth inhibition of human CCRF-HSB-2 cells by MTT method Growth inhibition of human CCRF-HSB-2 cells by MTT method	[PMID: 18819815]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by modified MTT assay Antitumor activity against human CCRF-HSB2 cells by modified MTT assay	[PMID: 17644399]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 17962027]
CCRF-HSB-2	IC₅₀	0.15 μM Compound: ara-C	Growth inhibition of human CCRF-HSB-2 cells by MTT assay Growth inhibition of human CCRF-HSB-2 cells by MTT assay	[PMID: 17049252]
CML/BC	IC₅₀	0.21 μM Compound: ara-C	Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis) Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)	[PMID: 3761322]
COLO 320	IC₅₀	0.04 μM Compound: ara-c	Tested in vitro against colo-320 human colon adenocarcinoma Tested in vitro against colo-320 human colon adenocarcinoma	[PMID: 8277499]
DLD-1	IC₅₀	> 5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against colon DLD-1 cells In vitro cytotoxicity was evaluated against colon DLD-1 cells	[PMID: 10780904]
Glioblastoma cell line	IC₅₀	> 100 μM Compound: ara-C	Compound was tested for the inhibition of glioblastoma Compound was tested for the inhibition of glioblastoma	[PMID: 3761322]
H22	IC₅₀	25.98 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	[PMID: 21620529]
H22	IC₅₀	37.82 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
HCT-116	GI₅₀	0.12 μM Compound: Ara-C	Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HCT-116	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human HCT116 cells after 24 hrs by MTT assay Antitumor activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 20211564]
HCT-116	IC₅₀	2.42 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
HCT-116	IC₅₀	4.4 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
HCT-116	IC₅₀	5.3 μM Compound: 1, ara-C	Cytotoxicity against human HCT116 cells by sulforhodamine B method Cytotoxicity against human HCT116 cells by sulforhodamine B method	[PMID: 19691349]
HCT-116	IC₅₀	5.3 μM Compound: 2, Ara-C	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24956556]
HCT-116	IC₅₀	5.3 μM Compound: AraC	Cytotoxicity against human HCT-116 cells Cytotoxicity against human HCT-116 cells	[PMID: 38716896]
HL-60	EC₅₀	0.6572 μM Compound: cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	ED₅₀	0.047 μM Compound: ara-C	Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+) Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)	[PMID: 3027329]
HL-60	ED₅₀	30 μM Compound: ara-C	Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined	[PMID: 3027329]
HL-60	IC₅₀	0.029 μg/mL Compound: ara-C	The cytotoxic activity in HL-60 cells The cytotoxic activity in HL-60 cells	[PMID: 9371251]
HL-60	IC₅₀	0.049 μM Compound: Ara-C	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.08 μM Compound: citarabine	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	0.118 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19321234]
HL-60	IC₅₀	0.13 μM Compound: ara-C	Compound was tested for the inhibition of human HL60 Leukemia Compound was tested for the inhibition of human HL60 Leukemia	[PMID: 3761322]
HL-60	IC₅₀	0.185 μM Compound: Cytarabine	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 30114661]
HL-60	IC₅₀	0.35 μM Compound: citarabine	In vitro concentration required to induce apoptosis in HL60R cells In vitro concentration required to induce apoptosis in HL60R cells	[PMID: 12877593]
HL-60	IC₅₀	0.76 μM Compound: ara-C	Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line	[PMID: 12954073]
HL-60	IC₅₀	> 0.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line. In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.	[PMID: 1995905]
HL-60	IC₅₀	> 0.1 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.	[PMID: 1992123]
HL60/MX2	EC₅₀	0.2612 μM Compound: cytarabine	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HOS-TE85	IC₅₀	10.7 μM Compound: ara-c	Tested in vitro against MNNG/HOS cell line human osteosarcoma Tested in vitro against MNNG/HOS cell line human osteosarcoma	[PMID: 8277499]
HOS-TE85	IC₅₀	2.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells	[PMID: 2002478]
HT-1080	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells	[PMID: 2002478]
HT-1080	IC₅₀	0.53 μM Compound: ara-c	Tested in vitro against HT1080 cell line human fibrosarcoma Tested in vitro against HT1080 cell line human fibrosarcoma	[PMID: 8277499]
HT-29	IC₅₀	66 nM Compound: cytosine arabinoside	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HUVEC	GI₅₀	0.23 μM Compound: Ara-C	Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay	[PMID: 22264170]
HeLa	ED₅₀	0.05 μg/mL Compound: AraC	Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis	[PMID: 178873]
HeLa	GI₅₀	0.18 μM Compound: Ara-C	Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HeLa	IC₅₀	0.23 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLa S3 cells Cytotoxicity against human HeLa S3 cells	[PMID: 10425135]
HeLa	IC₅₀	0.26 μM Compound: ara-C, cytarabine	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
HeLa	IC₅₀	0.95 μM Compound: ARA	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 29886320]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 23867603]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27073055]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HeLa	IC₅₀	464.433 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19321234]
HeLa S3	ED₅₀	2.13 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
HepG2	IC₅₀	0.2 μM Compound: Ara-C	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20692841]
HepG2	IC₅₀	2.86 μM Compound: Cytarabine	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 27073055]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	IC₅₀	26.23 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21620529]
HepG2	IC₅₀	38.1 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
Jurkat E6.1	IC₅₀	0.018 μM Compound: Cytarabine	Antiproliferative activity against human Jurkat E6-1 cells Antiproliferative activity against human Jurkat E6-1 cells	[PMID: 30114661]
K562	IC₅₀	0.05 μM Compound: 1, ara-C	Cytotoxicity against human K562 cells by sulforhodamine B method Cytotoxicity against human K562 cells by sulforhodamine B method	[PMID: 19691349]
K562	IC₅₀	0.05 μM Compound: 2, Ara-C	Cytotoxicity against human K562 cells by SRB assay Cytotoxicity against human K562 cells by SRB assay	[PMID: 24956556]
K562	IC₅₀	0.05 μM Compound: AraC	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 38716896]
K562	IC₅₀	14 μM Compound: Ara-C	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	24.29 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 21620529]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.	[PMID: 1992123]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines. In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.	[PMID: 3373480]
K562	IC₅₀	33.5 μM Compound: Ara-C	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 20692841]
K562	IC₅₀	43.61 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
K562	IC₅₀	500 mM Compound: ara-C	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 18571290]
K562	IC₅₀	500 nM Compound: ara-c	Inhibition of cell growth against human myeloid leukemia K562(S) cells Inhibition of cell growth against human myeloid leukemia K562(S) cells	[PMID: 10560743]
KB	ED₅₀	0.99 μg/mL Compound: Cytosine arabinoside	Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis	[PMID: 21194944]
KB	ED₅₀	2.84 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
KB	IC₅₀	0.14 μg/mL Compound: Ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 18055068]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by modified MTT assay Antitumor activity against human KB cells by modified MTT assay	[PMID: 17644399]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 17962027]
KB	IC₅₀	0.42 μg/mL Compound: AraC	Growth inhibition of human KB cells by MTT method Growth inhibition of human KB cells by MTT method	[PMID: 18819815]
KB	IC₅₀	0.64 μM Compound: ara-C	Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line	[PMID: 8277500]
KB	IC₅₀	0.7 μM Compound: ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 17049252]
KB	IC₅₀	0.73 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 18723355]
KB	IC₅₀	0.81 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 10425135]
KB	IC₅₀	0.99 μg/mL Compound: Cytarabine	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
KB	IC₅₀	2.3 μM Compound: ara-c	Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells	[PMID: 8277499]
KB	IC₅₀	30.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line. In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.	[PMID: 1995905]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 23867603]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 27073055]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KHOS-321H	IC₅₀	0.27 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells	[PMID: 2002478]
KKLS	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against KKLS human stomach adenocarcinoma Tested in vitro against KKLS human stomach adenocarcinoma	[PMID: 8277499]
L02	IC₅₀	0.17 μM Compound: ARA	Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
L02	IC₅₀	0.21 μM Compound: ARA	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
L1210	ED₅₀	0.03 μM Compound: ara-C	Inhibition of thymidylate synthase in L1210 cells Inhibition of thymidylate synthase in L1210 cells	[PMID: 3027329]
L1210	ED₅₀	0.05 μM Compound: ara-C	Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
L1210	ED₅₀	0.05 μM Compound: ara-C	Effective dose to inhibit the replication of L1210 cell line in vitro. Effective dose to inhibit the replication of L1210 cell line in vitro.	[PMID: 1995894]
L1210	ED₅₀	0.1 μM Compound: ara-C	Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay	[PMID: 118258]
L1210	ED₅₀	0.1 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line	[PMID: 7143370]
L1210	ED₅₀	0.19 μM Compound: ara-C	In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours. In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.	[PMID: 3968680]
L1210	ED₅₀	2.76 μg/mL Compound: cytosine arabinoside	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	0.0004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay	[PMID: 19674903]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
L1210	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against mouse L1210 cells after 2 days Cytotoxicity against mouse L1210 cells after 2 days	[PMID: 19910080]
L1210	IC₅₀	0.031 μM Compound: araC	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on multidrug-resistant L1210 leukemia cells. Inhibitory concentration on multidrug-resistant L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on parentral (sensitive) L1210 leukemia cells. Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.05 μM Compound: ara-c	Tested in vitro inhibitory activity against murine leukemia L1210 Tested in vitro inhibitory activity against murine leukemia L1210	[PMID: 8277499]
L1210	IC₅₀	0.08 μM Compound: araC	Inhibitory activity against murine leukemia L1210 cells Inhibitory activity against murine leukemia L1210 cells	[PMID: 1992143]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse. Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	[PMID: 1992123]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines. In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.	[PMID: 3373480]
L1210	IC₅₀	0.1 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.12 μM Compound: ara-C	Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse	[PMID: 8277500]
L1210	IC₅₀	0.17 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia L1210 Anticancer activity carried out in vitro against murine leukemia L1210	[PMID: 11356110]
L1210	IC₅₀	103 μM Compound: AraC, cytarabine	Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.04 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.62 μM Compound: ara-c	Tested in vitro against MCF-7 human breast adenocarcinoma Tested in vitro against MCF-7 human breast adenocarcinoma	[PMID: 8277499]
MCF7	IC₅₀	0.93 μg/mL Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
MCF7	IC₅₀	1.03 μM Compound: Ara-C	Anticancer activity carried out in vitro against breast carcinoma MCF-7 Anticancer activity carried out in vitro against breast carcinoma MCF-7	[PMID: 11356110]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23867603]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7cells after 72 hrs by SRB assay Cytotoxicity against human MCF7cells after 72 hrs by SRB assay	[PMID: 27073055]
MCF7	IC₅₀	3.82 μM Compound: ara-C	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	> 20 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay	[PMID: 35665692]
MCF7	IC₅₀	>= 100 μM Compound: Ara-C	Antitumor activity against human MCF7 cells after 24 hrs by MTT assay Antitumor activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20211564]
MDA-MB-231	IC₅₀	1.37 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
MDA-MB-231	IC₅₀	10.49 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
MES-SA	IC₅₀	1.7 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay	[PMID: 19674903]
MKN-28	IC₅₀	4.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells	[PMID: 2002478]
MKN-45	IC₅₀	57.6 μM Compound: ara-c	Tested in vitro against MKN-45 human stomach adenocarcinoma Tested in vitro against MKN-45 human stomach adenocarcinoma	[PMID: 8277499]
MOLT-3	ED₅₀	2.67 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
MOLT-4	IC₅₀	0.03 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
MOLT-4	IC₅₀	0.056 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.	[PMID: 1995905]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.	[PMID: 1992123]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.	[PMID: 3373480]
MOLT-4	IC₅₀	0.65 μM Compound: Ara-C	Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8 Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8	[PMID: 11356110]
MOLT-4	IC₅₀	1 μM Compound: Ara-C	Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay	[PMID: 20211564]
MOLT-4	IC₅₀	4.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
MPC-11	ED₅₀	0.99 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line	[PMID: 7143370]
MV4-11	IC₅₀	3.36 μM Compound: AraC	Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay	[PMID: 20153646]
NCC	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells	[PMID: 2002478]
NCI-H23	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1 In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1	[PMID: 10780904]
NCI-H460	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human H460 cells after 24 hrs by MTT assay Antitumor activity against human H460 cells after 24 hrs by MTT assay	[PMID: 20211564]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
NUGC-3	GI₅₀	0.25 μM Compound: Ara-C	Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
Non-small cell lung cancer cell line	IC₅₀	34 μM Compound: ara-C	Compound was tested for the inhibition of non- small cell lung cancer Compound was tested for the inhibition of non- small cell lung cancer	[PMID: 3761322]
OST	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against OST human osteosarcoma Tested in vitro against OST human osteosarcoma	[PMID: 8277499]
P388	ED₅₀	0.02 μM Compound: ara-C	Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
P388	ED₅₀	0.02 μM Compound: ara-C	Effective dose to inhibit the replication of P388 cell line in vitro. Effective dose to inhibit the replication of P388 cell line in vitro.	[PMID: 1995894]
P388	IC₅₀	0.14 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia P388 Anticancer activity carried out in vitro against murine leukemia P388	[PMID: 11356110]
P388	IC₅₀	1233 nM Compound: cytosine arabinoside	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	181 μM Compound: Cytarabin	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay	[PMID: 38064359]
PC-13	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line. In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.	[PMID: 1995905]
PC-13	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against PC-13 human lung large cell carcinoma Tested in vitro against PC-13 human lung large cell carcinoma	[PMID: 8277499]
PC-14	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line. In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.	[PMID: 1995905]
PC-14	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.	[PMID: 1992123]
PC-3	IC₅₀	0.81 μM Compound: ara-C	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
PC-3	IC₅₀	48.4 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
PC-3	IC₅₀	50.51 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
PC-3	IC₅₀	55.9 μM Compound: 1, ara-C	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 19691349]
PC-3	IC₅₀	55.9 μM Compound: 2, Ara-C	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 24956556]
PC-3	IC₅₀	55.9 μM Compound: AraC	Cytotoxicity against human PC-3 cells Cytotoxicity against human PC-3 cells	[PMID: 38716896]
PC-6	IC₅₀	50 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells	[PMID: 2002478]
PC-6	IC₅₀	50 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line. In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.	[PMID: 1995905]
PC-8	IC₅₀	0.28 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells	[PMID: 2002478]
PC-8	IC₅₀	1.1 μM Compound: ara-c	Tested in vitro against PC-8 human lung adenocarcinoma Tested in vitro against PC-8 human lung adenocarcinoma	[PMID: 8277499]
PC-9	IC₅₀	1.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells	[PMID: 2002478]
PC-9	IC₅₀	6.6 μM Compound: ara-c	Tested in vitro against PC-9 human lung adenocarcinoma Tested in vitro against PC-9 human lung adenocarcinoma	[PMID: 8277499]
PC10	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line. In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.	[PMID: 1995905]
PC10	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.	[PMID: 1992123]
PC10	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10). In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).	[PMID: 3373480]
QG-95	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against QG-95 human squamous cell carcinoma Tested in vitro against QG-95 human squamous cell carcinoma	[PMID: 8277499]
RPMI 6410	IC₅₀	6.0 x 10^-6 M Compound: Ara-C	Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
RS4-11	IC₅₀	0.26 μM Compound: AraC	Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay	[PMID: 20153646]
SAOS-2	IC₅₀	2.7 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells	[PMID: 2002478]
SF-268	IC₅₀	7.68 x 10^-3 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells by MTT assay Cytotoxicity against human SF268 cells by MTT assay	[PMID: 19345581]
SF-268	IC₅₀	7.68 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells after 3 days by MTT assay Cytotoxicity against human SF268 cells after 3 days by MTT assay	[PMID: 20356655]
SK-BR-3	IC₅₀	0.87 μM Compound: ara-C	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-ES1	IC₅₀	0.09 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells	[PMID: 2002478]
SK-HEP1	IC₅₀	1.8 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SK-HEP1	IC₅₀	2.12 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SK-MEL-28	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells	[PMID: 10780904]
SK-MEL-28	IC₅₀	11.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human melanoma (P-36) cell line. In vitro inhibitory activity against Human melanoma (P-36) cell line.	[PMID: 1995905]
SK-OV-3	IC₅₀	0.99 μM Compound: ara-C	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SMMC-7721	IC₅₀	0.013 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
SMMC-7721	IC₅₀	0.0271 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
SNB-7	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1 In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1	[PMID: 10780904]
SNU-638	IC₅₀	0.15 μM Compound: 1, ara-C	Cytotoxicity against human SNU638 cells by sulforhodamine B method Cytotoxicity against human SNU638 cells by sulforhodamine B method	[PMID: 19691349]
SNU-638	IC₅₀	0.15 μM Compound: 2, Ara-C	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 24956556]
SNU-638	IC₅₀	0.15 μM Compound: AraC	Cytotoxicity against human SNU-638 cells Cytotoxicity against human SNU-638 cells	[PMID: 38716896]
SNU-638	IC₅₀	1.08 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SNU-638	IC₅₀	3.98 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
ST-KM-1	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against ST-KM human stomach adenocarcinoma Tested in vitro against ST-KM human stomach adenocarcinoma	[PMID: 8277499]
SW-620	IC₅₀	30 μM Compound: Ara-C	Antitumor activity against human SW620 cells after 24 hrs by MTT assay Antitumor activity against human SW620 cells after 24 hrs by MTT assay	[PMID: 20211564]
SW1573	IC₅₀	10500 μM Compound: cytarabine	Cytotoxicity against SW1573 cells after 72 hrs by SRB assay Cytotoxicity against SW1573 cells after 72 hrs by SRB assay	[PMID: 17419604]
SW48	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against SW-48 human colon adenocarcinoma Tested in vitro against SW-48 human colon adenocarcinoma	[PMID: 8277499]
SW480	ED₅₀	3.42 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
SW480	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line. In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.	[PMID: 1995905]
SW480	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.	[PMID: 1992123]
SW480	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480). In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).	[PMID: 3373480]
Small cell lung cancer cell line	IC₅₀	> 100 μM Compound: ara-C	Compound was tested for the inhibition of small cell lung cancer Compound was tested for the inhibition of small cell lung cancer	[PMID: 3761322]
T-24	IC₅₀	0.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells	[PMID: 2002478]
T-24	IC₅₀	0.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line. In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.	[PMID: 1995905]
T-24	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.	[PMID: 1992123]
T-24	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24). In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).	[PMID: 3373480]
T47D	IC₅₀	2.7 μM Compound: 1, ara-C	Cytotoxicity against human T47D cells by sulforhodamine B method Cytotoxicity against human T47D cells by sulforhodamine B method	[PMID: 19691349]
T47D	IC₅₀	2.7 μM Compound: AraC	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 38716896]
T47D	IC₅₀	2.72 μM Compound: 2, Ara-C	Cytotoxicity against human T47D cells by SRB assay Cytotoxicity against human T47D cells by SRB assay	[PMID: 24956556]
TE-2	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line. In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.	[PMID: 1995905]
TE-2	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.	[PMID: 1992123]
TE-2	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2). In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).	[PMID: 3373480]
U-87MG ATCC	CC₅₀	0.19 μM Compound: 16	Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay	[PMID: 35123007]
U-87MG ATCC	IC₅₀	0.85 μM Compound: ara-C	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
U-87MG ATCC	IC₅₀	2.88 μM Compound: ara-C	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-937	IC₅₀	0.002 μM Compound: Cytarabine	Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay	[PMID: 30954427]
U-937	IC₅₀	0.31 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.	[PMID: 1992123]
U-937	IC₅₀	0.46 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line. In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.	[PMID: 1995905]
Vero	CC₅₀	4.8 μg/mL Compound: Ara-C	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	1.6 μg/mL Compound: Ara-C	Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	3 μg/mL Compound: Ara-C	Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
WI-38	IC₅₀	493.17 μM Compound: CAR	Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]
WI-38	IC₅₀	> 100 μg/mL Compound: CAR	Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay	[PMID: 35963130]

体外研究
(In Vitro)

Cytarabine 被磷酸化为三磷酸形式 (Ara-CTP)，涉及脱氧胞苷激酶 (dCK)，它与 dCTP 竞争掺入 DNA，然后通过抑制 DNA 和 RNA 聚合酶的功能来阻断 DNA 合成。与其他急性髓性白血病 (AML) 细胞相比，Cytarabine 对野生型 CCRF-CEM 细胞表现出更高的生长抑制活性，IC₅₀ 为 16 nM^[1]。
Cytarabine 在 10 μM 时明显诱导大鼠交感神经细胞凋亡，其中 100 μM 显示出最高毒性并在 84 小时内杀死超过 80% 的神经元，涉及线粒体细胞色素-c 的释放和 caspase-3 的激活，以及毒性可通过 p53 敲低减弱并通过 bax 缺失延迟^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cytarabine (250 mg/kg) 还会导致妊娠 Slc:Wistar 大鼠的胎盘生长迟缓并增加胎盘迷路区的胎盘滋养层细胞凋亡，从处理后 3 小时开始增加，并在 6 小时达到峰值，然后在 48 小时恢复到对照水平，并且 p53蛋白、p21、cyclinG1、fas 等 p53 转录靶基因和 caspase-3 活性显著增强^[3]。
Cytarabine 对急性白血病非常有效，这会导致 Cytarabine teristic G1/S 阻断和同步，并以弱剂量相关的方式增加白血病 Brown Norway 大鼠的存活时间，这表明使用更高剂量的 Cytarabine 不会有助于它在人类中的抗白血病作用^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

243.22

Formula

C₉H₁₃N₃O₅

CAS 号

147-94-4

性状

固体

颜色

White to off-white

中文名称

阿糖胞苷；阿糖胞嘧啶

结构分类

Others

初始来源

微生物

内源性代谢物

Xerocomus nigromaculatus

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性数据

细胞实验：

DMSO 中的溶解度 : 17.3 mg/mL (71.13 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.1115 mL	20.5575 mL	41.1150 mL
5 mM	0.8223 mL	4.1115 mL	8.2230 mL
10 mM	0.4112 mL	2.0558 mL	4.1115 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.55 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.55 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.55 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： PBS
Solubility: 100 mg/mL (411.15 mM); 澄清溶液; 超声助溶 (<60°C)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.98%

选择批次：

Data Sheet (661 KB) SDS (557 KB)

COA (290 KB) HNMR (263 KB) RP-HPLC (235 KB) LCMS (102 KB) 元素分析报告 (213 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief]

[2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief]

[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief]

[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief]

[5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief]

[6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief]

[7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief]

[8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Animal Administration ^[3]	Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief] [2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief] [3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief] [4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief] [5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief] [6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief] [7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief] [8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Animal Administration
^[3]

Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief]

[2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief]

[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief]

[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief]

[5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief]

[6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief]

[7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief]

[8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Cytarabine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.1115 mL	20.5575 mL	41.1150 mL	102.7876 mL
	5 mM	0.8223 mL	4.1115 mL	8.2230 mL	20.5575 mL
	10 mM	0.4112 mL	2.0558 mL	4.1115 mL	10.2788 mL
	15 mM	0.2741 mL	1.3705 mL	2.7410 mL	6.8525 mL
	20 mM	0.2056 mL	1.0279 mL	2.0558 mL	5.1394 mL
	25 mM	0.1645 mL	0.8223 mL	1.6446 mL	4.1115 mL
	30 mM	0.1371 mL	0.6853 mL	1.3705 mL	3.4263 mL
	40 mM	0.1028 mL	0.5139 mL	1.0279 mL	2.5697 mL
	50 mM	0.0822 mL	0.4112 mL	0.8223 mL	2.0558 mL
	60 mM	0.0685 mL	0.3426 mL	0.6853 mL	1.7131 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cytarabine147-94-4Cytosine β-D-arabinofuranoside Cytosine Arabinoside Ara-C阿糖胞苷阿糖胞嘧啶DNA/RNA SynthesisNucleoside Antimetabolite/AnalogHSVAutophagyEndogenous MetaboliteApoptosisOrthopoxvirusHerpes simplex virusInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Cytarabine (Synonyms: 阿糖胞苷; Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Customer Review

Other Forms of Cytarabine:

MCE 顾客使用本产品发表的 80 篇科研文献

Cytarabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSV 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Cytarabine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cytarabine (Synonyms: 阿糖胞苷; Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Customer Review

Other Forms of Cytarabine:

Cytarabine 相关抗体

MCE 顾客使用本产品发表的 80 篇科研文献

Cytarabine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 HSV 亚型特异性产品:

生物活性

实验参考方法

纯度 & 产品资料

参考文献

Cytarabine 相关抗体:

摩尔计算器

稀释计算器

Cytarabine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z